icon on the left to see more links.
This program includes Butler University, Regeneron Pharmaceuticals, and The Office of Medication Error Prevention and Risk Management (OMEPRM) at the USFDA. This program will have one (1) position available for a two-year term (July 2022 through June 2024).
Fellows will begin with the academic sector at Butler University from July–October 2022. They will then move into the industry sector, working with Regeneron Pharmaceuticals from November 2022–October 2023. Finally, fellows will learn from the regulatory sector, partnering with the Food and Drug Administration from November 2023–June 2024.
Applications are now closed for the 2022-2024 recruitment cycle. Please email rxfellowships@butler.edu with any questions you may have
Butler University College of Pharmacy and Health Sciences
July 2022–October 2022
Located in Indianapolis, Indiana, Butler University is a nationally recognized university with six academic colleges. In 2020, Butler was ranked as the top regional university in the Midwest by U.S. News & World Report, the most innovative among Midwest Regional Universities. At the Butler University College of Pharmacy & Health Sciences, you will find a community of health professionals committed to excellence. Our programs prepare students and post-graduate learners to become leaders in their chosen fields. Butler University College of Pharmacy and Health Sciences has a variety of post-graduate residencies and fellowships, each designed to strengthen not only the professionals’ specialty expertise, but also enhance teaching abilities in the classroom through faculty direction and mentorship.
Butler University College of Pharmacy and Health Sciences
4600 Sunset Avenue
Indianapolis, IN 46208
Regeneron Pharmaceuticals
November 2022–October 2023
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved medicines and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron Pharmaceuticals
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States Food and Drug Administration
November 2023–June 2024
Office of Medication Error Prevention and Risk Management (OMEPRM) includes Division of Medication Error Prevention and Analysis (DMEPA) and Division of Risk Management (DRISK). DMEPA looks to minimize medication errors in the U.S. healthcare system. As part of the FDA preapproval process for new drug products, we review proposed proprietary drug names, container labels and other labeling, packaging, product design, and human factors protocols and study results to prevent medication errors. We also monitor and analyze medication error reports for marketed products to determine if regulatory actions such as labeling revisions or product redesign are needed to address reported errors. DRISK reviews all proposed REMS, REMS modifications, and REMS assessments for all products with approved REMS for conformance with current FDA standards.
United States Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
This program includes Butler University, Eli Lilly and Company, and The Office of Medication Error Prevention and Risk Management (OMEPRM) at the USFDA. This program will have one (1) position available for a two-year term (July 2022 through June 2024).
Butler University College of Pharmacy and Health Sciences
July 2022—October 2022
Located in Indianapolis, Indiana, Butler University is a nationally recognized university with six academic colleges. In 2020, Butler was ranked as the top regional university in the Midwest by U.S. News & World Report, the most innovative among Midwest Regional Universities. At the Butler University College of Pharmacy & Health Sciences, you will find a community of health professionals committed to excellence. Our programs prepare students and post-graduate learners to become leaders in their chosen fields. Butler University College of Pharmacy and Health Sciences has a variety of post-graduate residencies and fellowships, each designed to strengthen not only the professionals’ specialty expertise, but also enhance teaching abilities in the classroom through faculty direction and mentorship.
Butler University College of Pharmacy and Health Sciences
4600 Sunset Avenue
Indianapolis, IN 46208
Eli Lilly and Company
November 2022—October 2023
For more than 140 years, Lilly has worked tirelessly to develop and deliver trusted medicines that meet real needs. Their growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain. Lilly’s Global Patient Safety organization, consisting of more than 300 physicians, pharmacists, nurses and other health care professionals are dedicated to the collection, monitoring, evaluation and reporting of safety information through the science of pharmacovigilance.
Eli Lilly and Company
893 Delaware St
Indianapolis, IN 46225
United States Food and Drug Administration
November 2023—June 2024
Office of Medication Error Prevention and Risk Management (OMEPRM) includes Division of Medication Error Prevention and Analysis (DMEPA) and Division of Risk Management (DRISK). DMEPA looks to minimize medication errors in the U.S. healthcare system. As part of the FDA preapproval process for new drug products, we review proposed proprietary drug names, container labels and other labeling, packaging, product design, and human factors protocols and study results to prevent medication errors. We also monitor and analyze medication error reports for marketed products to determine if regulatory actions such as labeling revisions or product redesign are needed to address reported errors. DRISK reviews all proposed REMS, REMS modifications, and REMS assessments for all products with approved REMS for conformance with current FDA standards.
United States Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993